Sanofi-Aventis Sa (SNY) Got Some Good News

Leerink Partners analyst Geoff Porges upgraded Sanofi-Aventis Sa (SNYResearch Report) to Buy today. The company’s shares closed last Friday at $47.94.

According to TipRanks.com, Porges is a 3-star analyst with an average return of 2.5% and a 47.9% success rate. Porges covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Vertex Pharmaceuticals, and Theravance Biopharma.

The the analyst consensus on Sanofi-Aventis Sa is currently a Moderate Buy rating.

See today’s analyst top recommended stocks >>

Sanofi-Aventis Sa’s market cap is currently $120.3B and has a P/E ratio of 15.60. The company has a Price to Book ratio of -83.54.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Founded in 1973, Sanofi is a France-based leading global healthcare company, which provides therapeutic solutions worldwide. It operates through business units including Pharmaceuticals (comprised of General Medicines and Speciality Care), Consumer Healthcare, and Vaccines.